Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Novo Nordisk recently raised its profit goals for the year. This change comes because many people want the new Wegovy pill. Doctors wrote over 1.3 million prescriptions in just three months. By middle April, that number grew to over 2…
Novo Nordisk recently released promising topline results from its PIONEER TEENS clinical trial. This study focused on the effectiveness of oral semaglutide for children and adolescents living with type 2 diabetes. Researchers specifically monitored participants between the ages of 10…
The Food and Drug Administration recently approved a new pill called orforglipron for weight management. This daily medication helps adults living with obesity or weight-related health issues. Patients should use this treatment along with healthy eating and regular exercise. Federal…
A new study in the journal Stigma and Health shows a clear social bias. Women using GLP-1 drugs for weight loss face more judgment than those who exercise. Researchers found that many people view these medications as a lazy shortcut.…
The ACHIEVE-4 trial recently confirmed the safety of a new oral drug called Foundayo. This study monitored 2,700 patients to see how the medication affects the heart and liver. Eli Lilly reported that the results met all safety requirements set…
The Food and Drug Administration has assigned Eli Lilly new requirements regarding its oral weight loss pill. This official order mandates several safety checks for the drug, Foundayo. Federal experts identified a few areas where they need more data on…
Individual genetic blueprints significantly determine how patients respond to modern pharmacological weight management. A comprehensive investigation recently analyzed specific genetic markers to predict whether a patient achieves substantial weight loss or suffers from debilitating side effects. Scientists reviewed clinical data…
Medical professionals currently face a significant question regarding type 2 diabetes management. They must determine if sodium-glucose cotransporter-2 inhibitors alter the cardiovascular benefits of semaglutide. Recent evidence from the SOUL and FLOW trials provides clear answers to this clinical inquiry.…
Recently, the federal government authorized the first-ever weight loss pill classified as GLP-1. This daily pill aids in weight loss and also safeguards heart health. Prior to this, patients typically needed to rely on weekly injections to achieve these results.…
For a long time, the “gold standard” for medical weight loss has come with a sharp caveat: you had to be okay with needles. Whether it was Wegovy or Zepbound, the path to a quieter “food noise” brain usually involved…